Agonists elevate the cytosolic calcium concentration in human platelets via a receptor-operated mechanism, involving both Ca 2؉ release from intracellular stores and subsequent Ca 2؉ entry, which can be inhibited by platelet inhibitors, such as prostaglandin E 1 and nitroprusside which elevate cAMP and cGMP, respectively. In the present study we investigated the mechanisms by which cAMP and cGMP modulate store-mediated Ca 2؉ entry. Both prostaglandin E 1 and sodium nitroprusside inhibited thapsigargin-evoked store-mediated Ca 2؉ entry and actin polymerization. However, addition of these agents after induction of store-mediated Ca 2؉ entry did not affect either Ca 2؉ entry or actin polymerization. Furthermore, prostaglandin E 1 and sodium nitroprusside dramatically inhibited the tyrosine phosphorylation induced by depletion of the internal Ca 2؉ stores or agonist stimulation without affecting the activation of Ras or the Ras-activated phosphatidylinositol 3-kinase or extracellular signal-related kinase (ERK) pathways. Inhibition of cyclic nucleotidedependent protein kinases prevented inhibition of agonistevoked Ca 2؉ release but it did not have any effect on the inhibition of Ca 2؉ entry or actin polymerization. Phenylarsine oxide and vanadate, inhibitors of protein-tyrosine phosphatases prevented the inhibitory effects of the cGMP and cAMP elevating agents on Ca 2؉ entry and actin polymerization. These results suggest that Ca 2؉ entry in human platelets is directly down-regulated by cGMP and cAMP by a mechanism involving the inhibition of cytoskeletal reorganization via the activation of protein tyrosine phosphatases.
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In platelets and other nonexcitable cells, receptor stimulation promotes the entry of extracellular Ca 2ϩ through the plasma membrane (1) . A major mechanism for Ca 2ϩ influx is store-mediated Ca 2ϩ entry (SMCE), 1 in which the filling state of the internal Ca 2ϩ stores regulates the entry of Ca 2ϩ (2) . Although mechanisms involved in the activation of this pathway are still not well understood, hypotheses have considered both indirect and direct coupling mechanisms. Indirect coupling assumes the existence of a diffusible messenger generated by the Ca 2ϩ storage organelles (3) (4) (5) (6) . The direct coupling (conformational coupling) hypothesis proposes a physical interaction between the endoplasmic reticulum and the plasma membrane (7) . Recently, a revised model for direct coupling, the secretion-like coupling model, has been proposed to operate in several cell types (8) , including human platelets (9) . The secretion-like coupling model is based on a reversible trafficking and coupling of the endoplasmic reticulum with the plasma membrane that, in platelets, appears to involve IP 3 receptors in the endoplasmic reticulum and TRP1 channels in the plasma membrane (10) .
In the secretion-like coupling model for SMCE, the actin cytoskeleton plays an important role, which has been demonstrated in several cell types (11, 12) , including platelets (5, 9) . Platelet activation is accompanied by a dramatic increase in tyrosine phosphorylation of many cellular proteins (13) . A role for protein tyrosine phosphorylation in the activation of SMCE has been reported on the basis of the correlation between depletion of the intracellular Ca 2ϩ and increases in phosphotyrosine levels, as well as the effects of different tyrosine kinase inhibitors on agonist and thapsigargin-evoked Ca 2ϩ entry (6, 14 -16) . We have recently reported that the effects of tyrosine kinases on SMCE are mediated through the reorganization of the actin cytoskeleton in human platelets (17) .
In contrast to platelet agonists, inhibitors of platelet activation, which elevate the levels of cAMP or cGMP, antagonize agonist-evoked increases in cytosolic calcium (1) . The mechanisms of action of cAMP and cGMP-elevating agents have been reported to involve the activation of cAMP-dependent and cGMPdependent protein kinases (PKA and PKG), which in turn inhibit agonist-induced Ca 2ϩ mobilization from the intracellular stores and hence SMCE (18, 19) . In the present study we sought to expand our understanding of the mechanisms by which cAMP and cGMP-elevating factors affect SMCE in platelets. We report here that prostaglandin E 1 (PGE 1 ) and the nitrovasodilator, sodium nitroprusside (SNP), which elevate the levels of cAMP and cGMP, respectively, inhibit agonistevoked Ca 2ϩ release, an action which is reversed by treatment with selective inhibitors of PKA and PKG, respectively. Our findings also indicate that PGE 1 and SNP inhibit both SMCE and actin polymerization by a mechanism independent of PKA and PKG and which requires activation of protein-tyrosine phosphatases. These results indicate that the inhibition of agonist-evoked elevations in [Ca 2ϩ ] i by cAMP-or cGMP-elevating agents might have two components: a reduction in Ca 2ϩ store depletion mediated by PKA or PKG, with a consequent reduction in SMCE, and a direct effect on Ca 2ϩ entry mediated by protein-tyrosine phosphatases and inhibition of actin polymerization.
EXPERIMENTAL PROCEDURES
Materials-Fura-2 acetoxymethyl ester (fura-2/AM) was from Texas Fluorescence (Austin, TX). Apyrase (grade V), aspirin, bovine serum albumin, paraformaldehyde, Nonidet P-40, fluorescein isothiocyanatelabeled phalloidin, thrombin, ADP, sodium nitroprusside, sodium vanadate, PGE 1 , and thapsigargin (TG) were from Sigma (Poole, Dorset, United Kingdom). KT5823, KT5720, ionomycin, and phenylarsine oxide (PAO) were from Calbiochem (Nottingham, UK). Anti-VASP Ser 239 monoclonal antibody was from Alexis Corp. (Nottingham, UK). Pan-Ras (Ab-3) monoclonal antibody was from Oncogene Science (Cambridge, MA). Phospho-p44/42 extracellular signal-regulated kinases (ERK) monoclonal antibody (E10) was from New England Biolabs (Beverly, MA). Anti-phosphotyrosine monoclonal antibody (4G10), anti-phosphoAkt/PKB␣ (Ser 473 ) monoclonal antibody, and horseradish peroxidaseconjugated rabbit anti-sheep IgG antibody were from Upstate Biotechnology (Lake Placid, NY). Horseradish peroxidase-conjugated ovine anti-mouse IgG antibody (NA931) was from Amersham Pharmacia Biotech (Little Chalfont, Bucks., UK). Dimethyl-bis-(o-aminophenoxy)-ethane-N,N,NЈ,NЈ-tetraacetic acid (BAPTA) acetoxymethyl ester was from Molecular Probes (Leiden, The Netherlands). All other reagents were of analytical grade.
Platelet Preparation-Fura-2-loaded platelets were prepared as described previously (5) . Briefly, blood was obtained from healthy volunteers and mixed with one-sixth volume of acid/citrate dextrose anticoagulant containing (in mM): 85 sodium citrate, 78 citric acid, and 111 D-glucose. Platelet-rich plasma was then prepared by centrifugation for 5 min at 700 ϫ g and aspirin (100 M) and apyrase (40 g/ml) added. Platelet-rich plasma was incubated at 37°C with 2 M fura-2/AM for 45 min. For loading with dimethyl-BAPTA, cells were incubated for 30 min at 37°C with 10 M dimethyl-BAPTA AM. Cells were then collected by centrifugation at 350 ϫ g for 20 min and resuspended in HEPESbuffered saline containing (in mM): 145 NaCl, 10 HEPES, 10 D-glucose, 5 KCl, 1 MgSO 4 , pH 7.45, and supplemented with 0.1% (w/v) bovine serum albumin and 40 g/ml apyrase.
Measurement of Intracellular Free Calcium Concentration ([Ca 2ϩ
] i )-Fluorescence was recorded from 1.5-ml aliquots of magnetically stirred platelet suspension (10 8 cells/ml) at 37°C using a Cairn Research Spectrophotometer (Cairn Research Ltd., Sittingbourne, Kent, UK) with excitation wavelengths of 340 and 380 nm and emission at 500 nm. ] i were monitored using the 340/380 nm ratio as described under "Experimental Procedures." Traces shown are representative of 6 to 11 independent experiments. 1 or SNP on TG-induced SMCE. Fura-2-loaded human platelets were incubated at 37°C in the presence of 5 M PGE 1 (A), 100 M SNP (B), or the vehicles (Control). At the time of the experiment 100 M EGTA was added. Cells were then stimulated with TG (200 nM) and 3 min later CaCl 2 (final concentration, 300 M) was added to the medium to initiate Ca 2ϩ entry. Elevations in [Ca 2ϩ ] i were monitored using the 340/380 nm ratio as described under "Experimental Procedures." Traces are representative of six to nine independent experiments. Changes in [Ca 2ϩ ] i were monitored using the fura-2 340/380 fluorescence ratio and calibrated according to the method of Grynkiewicz et al. (20) .
FIG. 2. Effects of PGE
Determination of Ca 2ϩ Entry-Ca 2ϩ influx in platelets that had been store depleted using TG was estimated using the integral of the rise in [Ca 2ϩ ] i for 2 1 ⁄2 min after addition of CaCl 2 (5 ] i above basal for 90 s after the addition of the agonist in the presence of external Ca 2ϩ or in a Ca 2ϩ -free medium (with 100 M EGTA), respectively. Measurement of F-actin Content-The F-actin content of resting and activated platelets was determined according to a previously published procedure (5) . Briefly, washed platelets (2 ϫ 10 8 cells/ml) were activated in HEPES-buffered saline. Samples of platelet suspension (200 l) were transferred to 200 l of ice-cold 3% (w/v) formaldehyde in phosphatebuffered saline (PBS) for 10 min. Fixed platelets were permeabilized by incubation for 10 min with 0.025% (v/v) Nonidet P-40 detergent dissolved in PBS. Platelets were then incubated for 30 min with fluorescein isothiocyanate-labeled phalloidin (1 M) in PBS supplemented with 0.5% (w/v) bovine serum albumin. After incubation the platelets were collected by centrifugation in an MSE Micro-Centaur Centrifuge (MSE Scientific Instruments, Crawley, Sussex, UK) for 60 s at 3000 ϫ g and resuspended in PBS. Staining of 2 ϫ 10 7 cells/ml was measured using a PerkinElmer Fluorescence Spectrophotometer (PerkinElmer Life Sciences, Norwalk, CT). Samples were excited at 496 nm and emission was at 516 nm.
Protein Tyrosine Phosphorylation-Protein tyrosine phosphorylation was detected by gel electrophoresis and Western blotting (6) . Platelets stimulation was terminated by mixing with an equal volume of 2 ϫ Laemmli's buffer (21) with 10% dithiothreitol followed by heating for 5 min at 95°C. One-dimensional SDS electrophoresis was performed with 10% polyacrylamide minigels and separated proteins were electrophoretically transferred, for 2 h at 0.8 mA/cm 2 , in a semi-dry blotter (Hoefer Scientific, Newcastle, Staffs., UK) onto nitrocellulose for subsequent probing. Blots were incubated overnight with 10% (w/v) bovine serum albumin in Tris-buffered saline with 0.1% Tween 20 (TBST) to block residual protein-binding sites. Immunodetection of tyrosine phosphorylation was achieved using the anti-phosphotyrosine antibody 4G10 diluted 1:2500 in TBST for 1 h. The primary antibody was removed and blots washed six times for 5 min each with TBST. To detect the primary antibody, blots were incubated with horseradish peroxidase-conjugated ovine anti-mouse IgG antibody diluted 1:10000 in TBST, washed six times in TBST, and exposed to enhanced chemiluminescence reagents for 1 min. Blots were then exposed to preflashed photographic film. Densitometric measurements were made using a Quantimet 500 densitometer (Leica, Milton Keynes, UK).
Quantitative analysis of VASP Ser 239 Phosphorylation-Phosphorylation of the residue Ser 239 of VASP, a phosphorylation site preferred by PKG but also used by PKA (22) , was measured by SDS-PAGE and Western blotting as described above but using a specific anti-VASP Ser 239 monoclonal antibody (16C2) diluted 1:1000 in TBST as previously described (22) .
Analysis of Akt/PKB␣ Ser 473 Phosphorylation-Phosphorylation of Akt/PKB␣ on the residue Ser 473 was assessed by SDS-PAGE and Western blotting as described above but using a specific anti-phospho-Akt/ PKB␣ (Ser 473 ) monoclonal antibody diluted 1:1500 in TBST as previously described (23) , followed by incubation with horseradish peroxidase-conjugated rabbit anti-sheep IgG antibody diluted 1:10000 in TBST.
Analysis of Diphosphorylated p42/p44 ERK-Analysis of diphosphorylated p42/p44 ERK was performed by SDS-PAGE and Western blotting as described above but using a specific phospho-p44/42 MAP kinase monoclonal antibody (E10) diluted 1:1500 in TBST as previously described (24). Fura-2-loaded human platelets were suspended in a Ca 2ϩ -free medium (100 M EGTA added) as described under "Experimental Procedures." Cells were then stimulated with TG (200 nM) and, 3 min later, 5 M PGE 1 , 100 M SNP, or the vehicles (Control) were added, as indicated by the arrow. CaCl 2 (final concentration 300 M) was added to the medium 1 min after SNP, PGE 1 , or the vehicles to initiate Ca 2ϩ entry. Elevations in [Ca 2ϩ ] i were monitored using the 340/380 nm ratio as described under "Experimental Procedures." Traces are representative of six independent experiments. HBS, HEPES-buffered saline.
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Subcellular Fractionation-Human platelet fractionation was carried out according to a previously published procedure (5) . Briefly, platelets were pelleted in a microcentrifuge and the pellets were quickly resuspended in 0.5 ml of ice-cold Tris-HCl buffer containing: 10 mM Tris-HCl (pH 7.2), 158 mM NaCl, 1 mM EGTA, 50 g/ml leupeptin, 5 mM benzamidine, 1 mM phenylmethylsulfonyl fluoride, and 1 mM Na 3 VO 4 . The suspensions were sonicated and intact platelets were removed by centrifugation at 1,500 ϫ g. The platelet lysate was centrifuged at 100,000 ϫ g at 4°C for 60 min to obtain membrane and cytosolic fractions. Membranes were washed with PBS with 1 mM Na 3 VO 4 at 4°C and resuspended in Tris-HCl buffer containing: 10 mM Tris-HCl, pH 7.2, 158 mM NaCl, 1 mM EGTA, 0.1% SDS, 1% sodium deoxycholate, 1% Triton X-100, 50 g/ml leupeptin, 5 mM benzamidine, 1 mM phenylmethylsulfonyl fluoride, and 1 mM Na 3 VO 4 . Lysates were centrifuged at 16,000 ϫ g for 5 min to remove insoluble substances. Lysates of the subcellular fractions or total cell lysates (50 g/well) were analyzed by Western blotting with pan-Ras (Ab-3) monoclonal antibody diluted 1:500 in TBST. To detect the primary antibody, blots were incubated with horseradish peroxidase-conjugated anti-mouse IgG antibody diluted 1:10,000 in TBST and exposed to enhanced chemiluminescence reagents for 1 min as described above. Blots were then exposed to preflashed photographic film.
Statistical Analysis-Analysis of statistical significance was performed using Student's t test. For multiple comparisons, one-way analysis of variance combined with the Dunnett test was used.
RESULTS

Regulation of Agonist-induced Ca
2ϩ Mobilization by PGE 1 and SNP-Treatment of fura-2-loaded human platelets with the physiological agonists thrombin (0.1 unit/ml) or ADP (40 M) evoked rises in [Ca 2ϩ ] i in both a medium containing 1 mM Ca 2ϩ and in the absence of external Ca 2ϩ (100 M EGTA was added). In agreement with previous studies (18, 19) thrombinand ADP-induced Ca 2ϩ elevations in human platelets were significantly inhibited when the cells were preincubated for 1 min with 5 M PGE 1 or 100 M SNP ( Fig. 1 ; p Ͻ 0.01; n ϭ 6 -11). In contrast, PGE 1 and SNP had no effect on resting [Ca 2ϩ ] i ( Fig. 1 Fig. 2 ; p Ͻ 0.001; n ϭ 6 -9). Platelets preincubated for 1 min with 5 M PGE 1 or 100 M SNP showed an identical release of Ca 2ϩ from the intracellular stores after treatment with TG in comparison with untreated cells (99.04 Ϯ 1.9 and 98.8 Ϯ 2.6% of control after treatment with PGE 1 or SNP, respectively).
Regulation of Actin Polymerization by PGE 1 or SNP in Human Platelets-Recently a role for the actin cytoskeleton in the activation of SMCE has been suggested in several cells types (11, 12, 26 ). As we have previously shown (17) , TG induces actin polymerization in the absence of a detectable rise in [Ca 2ϩ ] i in platelets loaded with the Ca 2ϩ chelator dimethyl-BAPTA. After dimethyl-BAPTA loading, treatment of platelets with 1 M TG in a Ca 2ϩ -free medium raised the F-actin content by 29.7 Ϯ 6.4% compared with control unstimulated cells. Treatment with various concentrations of PGE 1 or SNP did not significantly modify the F-actin content of resting platelets; however, TG-induced actin polymerization was inhibited in a concentration-dependent manner, with IC 50 values of 53.0 Ϯ 2.9 nM and 1.7 Ϯ 0.4 M, respectively, and complete inhibition at 5 and 100 M, respectively ( Fig. 3 ; p Ͻ 0.05; n ϭ 6).
Stimulation of dimethyl-BAPTA-loaded human platelets with thrombin (0.1 unit/ml) or ADP (40 M) for 3 min increased F-actin content by 32.1 Ϯ 3.2% and 23.6 Ϯ 2.1% of control, respectively. Consistent with the above, treatment of platelets with 5 M PGE 1 or 100 M SNP abolished both thrombin-and ADP-induced actin polymerization (data not shown).
Effect of PGE 1 and SNP on the Maintenance of Store-mediated Ca
2ϩ Entry-We have previously reported that the integrity of the actin cytoskeleton is essential for both the activation and maintenance of SMCE in platelets (9) . To investigate the effects of cAMP and cGMP on the maintenance of SMCE we examined the effect of PGE 1 and SNP, respectively, on Ca 2ϩ entry in platelets after SMCE had been previously stimulated using TG. Fig. 4 shows the effect of adding PGE 1 or SNP to storedepleted human platelets. 5 M PGE 1 (Fig. 4A) , 100 M SNP (Fig. 4B) , or the vehicles were added 3 min after TG and cells were then incubated for a further 1 min before the addition of Ca 2ϩ to the medium (final concentration 300 M) to initiate Ca 2ϩ entry. At the time when PGE 1 and SNP were added Ca 2ϩ entry was already stimulated (data not shown, but see Fig. 2 ). Addition of PGE 1 or SNP after Ca 2ϩ store depletion did not significantly modify subsequent Ca 2ϩ entry ( Fig. 4 ; p ϭ 0.87; n ϭ 6). Consistent with these results, treatment of human platelets for 1 min with 5 M PGE 1 or 100 M SNP after SMCE had been activated by the addition of TG did not alter TGevoked increase in the F-actin content (Table I ; n ϭ 6). These findings show that cAMP and cGMP inhibit the activation but not the maintenance of SMCE. In addition, these observations indicate that PGE 1 and SNP do not act either as Ca 2ϩ channel blockers or Ca 2ϩ chelators or as nonspecific inhibitors of actin polymerization.
Role of PKA and PKG in the Inhibitory Effects of PGE 1 and SNP on Actin Polymerization-To investigate the possible roles of PKA and PKG in the responses observed after treatment with PGE 1 and SNP we used KT5720 and KT5823, highly specific, cell-permeant inhibitors of PKA and PKG activity, respectively (27) . Since VASP has been reported to be a substrate for both PKA and PKG (22, 28) and the residue Ser 239 is the site preferred by PKG is also used by PKA in platelets (29, 30) , we monitored PKA and PKG activity by testing the effect of the inhibitors on PGE 1 -and SNP-induced phosphorylation of this residue. As shown in Treatment of human platelets for 30 min with 3 M KT5720 or 1 M KT5823 did not alter the F-actin content of unstimulated platelets. In addition, these treatments did not reverse the inhibitory effects of PGE 1 or SNP, respectively, on actin (Table II ; n ϭ 6). These results indicate that the effects of PGE 1 and SNP are independent of PKA and PKG, respectively. PGE 1 and SNP Prevent Protein Tyrosine Phosphorylation in Human Platelets-Agonist-and store depletion-induced protein tyrosine phosphorylation was assessed by gel electrophoresis and Western blotting with a specific antiphosphotyrosine antibody. Platelets heavily loaded with the Ca 2ϩ chelator dimethyl-BAPTA were used for this study so as to eliminate Ca 2ϩ -dependent tyrosine phosphorylation (31). Dimethyl-BAPTA-loaded platelets were incubated for 1 min at 37°C with 5 M PGE 1 or 100 M SNP or the vehicle and Ca 2ϩ stores were depleted using TG (1 M). Samples for protein phosphorylation analysis were taken from the spectrophotometer cuvette 10 s prior the addition of PGE 1 , SNP, or the vehicle and 10 s before and 10 and 180 s after the addition of TG. As shown in Fig. 6, A and B, pretreatment with PGE 1 or SNP significantly reduced protein tyrosine phosphorylation relative to its control in store depleted cells (e.g. bands at 72 and 130 kDa; n ϭ 4). Similar results were observed when cells were stimulated with the physiological agonists thrombin (0.1 unit/ ml; Fig. 6C and D ; n ϭ 4) and ADP (40 M; not shown). In addition, treatment with 5 M PGE 1 or 100 M SNP significantly reduced tyrosine phosphorylation in unstimulated platelets by 20 Ϯ 5 and 25 Ϯ 5%, respectively (p Ͻ 0.01; n ϭ 4).
Effect of Protein-tyrosine Phosphatases on PGE 1 -and SNP-
induced Responses-The possibility that the inhibitory effects observed after treatment with PGE 1 or SNP might be mediated by protein-tyrosine phosphatases was tested by examining the effect of the tyrosine phosphatase inhibitors PAO and vanadate. Under our conditions, treatment of dimethyl-BAPTAloaded human platelets for 30 min with either 10 M PAO or 100 M vanadate increased the phosphotyrosine level of both resting and stimulated cells without impairing TG-induced increase in the phosphotyrosine level ( Fig. 7 ; n ϭ 4). Interestingly, preincubation of platelets with 10 M PAO or 100 M vanadate for 30 min completely reversed the inhibition of actin polymerization observed after treatment with PGE 1 or SNP (Table II ; n ϭ 6), while this treatment per se did not modify either the F-actin content of unstimulated cells or TG-induced actin polymerization (data not shown).
Next we tested whether the inhibition of SMCE could be mediated by the activation of tyrosine phosphatase activity. Cells treated with PAO or vanadate showed similar resting levels of [Ca 2ϩ ] i to control platelets (data not shown). In addition, PAO or vanadate-treated cells retained their ability to respond to Ca 2ϩ mobilizing agents, such as TG, which indicates that this treatment did not affect the ability of platelets to store Ca 2ϩ in intracellular compartments as well as demonstrating that these agents per se do not mobilize Ca 2ϩ from the stores in platelets (data not shown). Platelets previously preincubated for 30 min with 10 M PAO or 100 M vanadate were treated for 
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1 min with PGE 1 , SNP, or the vehicles and then stimulated with TG (200 nM) in a Ca 2ϩ -free medium and 3 min later CaCl 2 (final concentration 300 M) was added. As shown in Table III , incubation with protein-tyrosine phosphatase inhibitors almost completely reversed the inhibitory effect of PGE 1 and SNP on SMCE. In contrast, PGE 1 and SNP inhibited SMCE to the same extent in control cells or in platelets preincubated for 30 min with the PKA and PKG inhibitors, KT5720 (3 M) and KT5823 (1 M), respectively (Table III ; n ϭ 6 -10). These findings are consistent with the role of protein-tyrosine phosphatases in actin filament polymerization and indicate that the effect exerted by cyclic nucleotides on SMCE is independent of PKA and PKG.
The effect of PGE 1 and SNP on thrombin-evoked Ca 2ϩ mobilization is shown in Table IV . The effects of either PGE 1 (5 M) or SNP (100 M) on thrombin-evoked Ca 2ϩ release were almost completely reversed by pretreatment for 30 min with 3 M KT5720 or 1 M KT5823, respectively, in contrast, 10 M PAO or 100 M vanadate had negligible effects (Table IV ; n ϭ 6). Pretreatment of platelets with KT5720 or KT5823 partially reversed the effect of PGE 1 or SNP on thrombin-induced Ca 2ϩ responses in a medium containing 1 mM Ca 2ϩ (Table IV ; p Ͻ 0.05; n ϭ 6). Similar results were obtained when platelets were treated with PAO or vanadate (Table IV ; p Ͻ 0.05; n ϭ 6). More importantly, the combined effect of inhibitors of either PKA or PKG and of tyrosine phosphatases completely prevented the inhibition induced by PGE 1 and SNP on thrombin-induced Ca 2ϩ elevations in the presence of 1 mM external Ca 2ϩ (Table  IV ; p Ͻ 0.001; n ϭ 6).
Role of the Ras-dependent Pathways on PGE 1 -and SNPinduced Responses-The activity of Ras proteins has been shown to be required for the activation of SMCE in several cell types (32, 33) including platelets (5) . To investigate whether PGE 1 and SNP impair the activation of Ras we have examined their effects on the association of Ras with membranes, a process essential for Ras activation (34) . In resting platelets, pan- Dimethyl-BAPTAloaded platelets were incubated for 1 min with 5 M PGE 1 (A and C, lanes 5-8) , 100 M SNP (B and D; lanes 5-8) , or the vehicles as control (lanes 1-4) and then stimulated with TG (1 M) or thrombin (0.1 unit/ml). At the times indicated 100-l aliquots were removed and the reaction terminated by mixing with an equal volume of 2 ϫ Laemmli's buffer with 10% dithiothreitol. Proteins were analyzed by SDS-PAGE and subsequent Western blotting with a specific antiphosphotyrosine antibody as described under "Experimental Procedures." Molecular size is indicated on the right. The panels show results from an experiment representative of three others.
FIG. 7.
Effect of PAO or vanadate on TG-stimulated protein tyrosine phosphorylation. Dimethyl-BAPTA-loaded platelets were incubated for 30 min with 10 M PAO, 100 M vanadate, or the vehicles (Control) and then stimulated with TG (1 M). At the times indicated 100-l aliquots were removed and the reaction terminated by mixing with an equal volume of 2 ϫ Laemmli's buffer with 10% dithiothreitol. Proteins were analyzed by SDS-PAGE and subsequent Western blotting with a specific antiphosphotyrosine antibody as described under "Experimental Procedures." Molecular size is indicated on the right. The panels show results from a representative experiment of three others.
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Ras immunoreactive proteins were detected in both cytosolic and membrane fractions (Fig. 8A) . As reported previously (5), TG induces translocation of Ras to the membrane fraction, an effect that was unmodified when platelets were incubated for 1 min with either PGE 1 or SNP (Fig. 8A, n ϭ 3) , treatments which also did not alter the distribution of Ras in resting cells (data not shown). We also investigated the effect of PGE 1 and SNP on the activation of phosphatidylinositol 3-kinase (PI3K) and ERK, which have been proposed as candidates for the cytoskeleton-dependent and -independent branches of the Rasdependent activation of SMCE in platelets, respectively (35 (36) . As shown in Fig. 8B , treatment of platelets with TG (200 nM) resulted in an increase in phosphorylation of Akt/PKB␣ on Ser 473 by 4.7 Ϯ 1.2-fold. This increase was abolished by preincubation for 30 min with 10 M LY 294002, a concentration that selectively inhibits PI3K activity (35) (Fig. 8B; n ϭ 3) . In contrast, treatment for 1 min with PGE 1 or SNP did not modify either basal or TG-induced phosphorylation of Akt/PKB␣ on Ser 473 , indicating that these agents do not affect PI3K activity. Similar results were obtained when the effect of these agents on TG-induced ERK activation was investigated. ERK activation was determined using an antibody that specifically recognizes diphosphorylated and thus activated p42/44 ERK as previously described (24) . We have recently found that TG induces ERK activation in human platelets, an action which is downstream of Ras activation. 2 As shown in Fig. 8C , treatment of platelets for 1 min with PGE 1 or SNP did not alter either basal or TG-induced ERK activation (n ϭ 3). Together, these results indicate that PGE 1 -or SNP-induced inhibition of Ca 2ϩ entry is independent on the Ras-mediated activation of SMCE in human platelets.
Regulation of Plasma Membrane Ca 2ϩ -ATPase Activity by SNP-Previous studies have shown that increasing platelet cytosolic cAMP with PGE 1 or forskolin stimulates plasmamembrane Ca 2ϩ -ATPase (PMCA) activity in these cells (31) . Using a previously published protocol (37) we have investigated the possible effect of cGMP on PMCA activity. In a Ca 2ϩ -free medium (100 M EGTA added), inhibition of SERCA using 1 M TG in the presence of a low concentration of ionomycin (50 nM; required for extensive depletion of the intracellular Ca 2ϩ stores in platelets), resulted in a transient increase Fura-2-loaded human platelets were incubated for 30 min at 37°C with 3 M KT5720, 1 M KT5823, 100 M sodium vanadate, 10 M PAO or the vehicles. At the time of the experiment 100 M EGTA was added. Cells were then incubated for 1 min with 5 M PGE 1 , 100 M SNP or the vehicle and stimulated with TG (200 nM) and 3 min later CaCl 2 (final concentration 300 M) was added to the medium to initiate Ca 2ϩ entry. Elevations in [Ca 2ϩ ] i were monitored using the 340/380 nm ratio as described under "Experimental Procedures." Data indicate the percentage of Ca 2ϩ entry relative to respective controls (vehicle was added). Ca 2ϩ entry was estimated as described under "Experimental Procedures." Values are mean Ϯ S.E. of six to ten separate determinations. Fura-2-loaded human platelets were incubated for 30 min at 37°C with 3 M KT5720, 1 M KT5823, 100 M sodium vanadate, 10 M PAO, a combination of KT5720 or KT5823 plus sodium vanadate or PAO or the vehicles. At the time of the experiment 1 mM Ca 2ϩ or 100 M EGTA was added. Cells were then incubated for 1 min with 5 M PGE 1 or 100 M SNP and stimulated with thrombin (0.1 unit/ml). Elevations in [Ca 2ϩ ] i were monitored using the 340/380 nm ratio and thrombin-induced Ca 2ϩ elevations and release were estimated by integration as described under "Experimental Procedures." Data indicate the percentage of Ca 2ϩ elevation or release relative to controls (vehicle was added). Values are mean Ϯ S.E. of six determinations. Several studies in platelets have reported that the effects of cyclic nucleotides on the Ca 2ϩ entry process are secondary to their inhibitory effects on intracellular Ca 2ϩ release (18, 19, 38) . In the present study we shed new light on the mechanism of action of cyclic nucleotides on SMCE. By reducing the preincubation time with the cAMP-and cGMP-elevating agents we were able to detect for the first time substantial inhibition of SMCE without the modification of TG-induced release. These findings strongly suggest that cyclic nucleotides exert a negative regulation of Ca 2ϩ entry independently of the extent of release from intracellular Ca 2ϩ stores. Recently it has been reported that the integrity of the actin cytoskeleton is required for the activation and maintenance of SMCE in different cell types (11, 12) , including platelets (5, 9) . Hence, we have investigated whether cyclic nucleotides interfere with actin polymerization. Treatment of platelets with the cAMP-and cGMP-elevating agents, PGE 1 and SNP, inhibited actin polymerization stimulated by TG or the physiological agonists ADP and thrombin. This inhibition of actin polymerization was observed in cells heavily loaded with the Ca 2ϩ chelator dimethyl-BAPTA, and thus was independent of any effects of the cyclic nucleotides on [Ca 2ϩ ] i . These results, together with the degree of inhibition of SMCE, are consistent with the effects of the inhibitors of actin polymerization cytochalasin D and latrunculin A on SMCE in human platelets (5, 9) . These agents inhibited SMCE by 50% at concentrations that abolished actin polymerization in platelets. Therefore, these findings suggest that the effect of cyclic nucleotides on SMCE might be mediated by impairment of actin filament polymerization.
Previous studies have shown that the effects of cyclic nucleotides are not mediated by acceleration of Ca 2ϩ removal from the cytosol (38) . Since more recent studies have shown that 
cAMP stimulates PMCA activity (31), we performed a series of studies to test the effects of cGMP on Ca 2ϩ extrusion. We have reported that the main mechanism for Ca 2ϩ extrusion in human platelets is the PMCA (37, 39 ). Our findings demonstrate that, as well as cAMP-elevating agents (31), SNP significantly increases Ca 2ϩ extrusion in platelets, a process that is entirely mediated by the PKG, since inhibition of this kinase abolished the effect of SNP. To evaluate whether Ca 2ϩ entry is directly down-regulated by the cyclic nucleotides or if their effects are mediated by acceleration of Ca 2ϩ extrusion we added PGE 1 or SNP to the platelet suspension once store-mediated Ca 2ϩ entry had been preactivated using TG. Our results show that treatment with cAMP-and cGMP-elevating agents after the activation of SMCE has no effect on Ca 2ϩ entry, while PMCA activity is increased. These observations indicate that, in agreement with previous studies (38) , cyclic nucleotides do not inhibit elevations in [Ca 2ϩ ] i by accelerating Ca 2ϩ extrusion alone, but that cAMP and cGMP are also involved in regulating the activation but not the maintenance of SMCE in platelets. Consistent with this, neither PGE 1 nor SNP impaired actin polymerization in preactivated platelets.
Most cellular functions exerted by cyclic nucleotides are mediated by the activation of cAMP-dependent and cGMP-dependent protein kinases. To determine whether PKA and PKG mediate these responses we used KT5720 and KT5823, selective cell-permeant inhibitors of PKA and PKG, respectively (27) . By monitoring PKA and PKG activity we found that treatment of platelets for 1 min with 5 M PGE 1 or 100 M SNP effectively activated PKA or PKG activity, respectively. Our present results and numerous previous studies with cAMPand cGMP-elevating agents (for review, see Refs. 1, 18, and 19) suggest that inhibition of agonist evoked intracellular Ca 2ϩ discharge is an effect mediated by both PKA and PKG. Although phosphorylation of VASP correlates with the inhibition of Ca 2ϩ release, at present we do not have evidence for the involvement of VASP in this process. However, a recent report has shown that VASP is not required for the inhibition of Ca 2ϩ mobilization in murine platelets mediated by cAMP-and cGMP-elevating agents (28) . In contrast, the analysis of the F-actin content and SMCE clearly excluded PKA and PKG as candidate proteins involved in cyclic nucleotide-mediated regulation of actin polymerization and Ca 2ϩ entry, since these processes were unaffected by KT5720 or KT5823. The partial recovery observed in thrombin-induced Ca 2ϩ elevation in the presence of 1 mM external Ca 2ϩ after incubation with KT5720 or KT5823 can be explained by the effect of these inhibitors on PGE 1 -and SNP-induced reductions in Ca 2ϩ release. Different results have been reported in vascular endothelial cells where cGMP inhibits SMCE via a PKG-dependent mechanism (40) .
An alternative pathway, responsible for the inhibitory effects of cAMP-and cGMP-elevating agents on Ca 2ϩ entry and actin polymerization, remains to be identified. Platelet activation is accompanied by a dramatic increase in tyrosine phosphorylation of many cellular proteins (13) . A role for protein tyrosine phosphorylation in the regulation of SMCE and actin polymerization has been proposed on the basis of the correlation between increases in phosphotyrosine levels and the filling state of the Ca 2ϩ stores, as well as the effects of different tyrosine kinase inhibitors on agonist and thapsigargin-evoked Ca 2ϩ entry and actin polymerization (14 -17) . In agreement with previous studies (38, 41) , we have found that cAMP-and cGMP-elevating agents inhibit agonist-or TG-stimulated tyrosine phosphorylation in dimethyl-BAPTA-loaded platelets. Therefore, we investigated whether protein-tyrosine phosphatases might be involved in the inhibitory effects of cAMPand cGMP-elevating agents. Treatment of platelets with the protein-tyrosine phosphatase inhibitors, PAO and vanadate, prevented the effect of both PGE 1 and SNP on actin polymerization and SMCE. We have found that PAO and vanadate do not impair agonist-evoked increases in phosphotyrosine levels. In addition, this treatment per se did not alter either basal or stimulated F-actin content or SMCE. These data suggest that the inhibitory effects of cAMP-and cGMP-elevating agents on actin polymerization and SMCE are mediated by the activation of tyrosine phosphatases. These findings are in agreement with earlier reports showing a role for tyrosine kinases in actin reorganization (17) and SMCE (14 -16) . Consistent with a recent study providing evidence that suggests that tyrosine kinases and Ras proteins have independent effects in the activation of SMCE in human platelets (17), we have found that treatment with PGE 1 or SNP did not interfere with Ras activation or the Ras-activated PI3K or ERK pathways. The effect of tyrosine phosphatases on cAMP and cGMP-induced inhibitions of agonist-evoked Ca 2ϩ mobilization is more complex. Our results indicate that tyrosine phosphatases are not involved in the effects of cyclic nucleotides on Ca 2ϩ release from the intracellular stores, which appear to be mediated entirely through PKA and PKG. However, the effects of cAMP and cGMP on agonist-evoked elevations in [Ca 2ϩ ] i as a whole (which involves Ca 2ϩ release and entry) are dependent on both cyclic nucleotidedependent kinases, which regulate Ca 2ϩ release, and tyrosine phosphatases, which are involved in the inhibition of Ca 2ϩ entry. Thus, the effects of cAMP-and cGMP-elevating agents, 
which are partially impaired by the inhibition of either of these pathways, are abolished by the inhibition of both.
In conclusion, we report here for the first time that SMCE in human platelets is directly down-regulated by cAMP and cGMP by a mechanism involving the activation of protein-tyrosine phosphatases. Therefore, two different cyclic nucleotide-dependent mechanisms operate during the regulation of agonist-induced Ca 2ϩ elevation: a PKA-/PKG-dependent mechanism for the inhibition of Ca 2ϩ release and a PKA-/PKG-independent tyrosine phosphatasedependent mechanism for the direct inhibition of Ca 2ϩ entry. The findings that cAMP and cGMP-elevating agents prevent the activation of SMCE, but not its maintenance, via the activation of tyrosine phosphatases is consistent with earlier observations indicating a role for tyrosine kinases in the activation but not in the maintenance of SMCE (17) .
